Latest News for: diffuse large b-cell lymphoma

Edit

Diffuse Large B-Cell Lymphoma Pipeline Outlook Report 2025: Key 70+ Companies and Breakthrough Therapies Shaping ...

GetNews 06 Aug 2025
Inactive Products Diffuse Large B-Cell Lymphoma Key Companies Diffuse Large B-Cell Lymphoma Key Products Diffuse Large B-Cell Lymphoma- Unmet Needs Diffuse Large B-Cell Lymphoma- Market Drivers and ...
Edit

Diffuse Large B-cell Lymphoma Market Analysis and Forecast Report 2025-2035 | Pharma Giants Such as ...

The Milton Standard Journal 05 Aug 2025
DUBLIN--(BUSINESS WIRE)--Aug 5, 2025-- ....
Edit

Diffuse Large B-cell Lymphoma Market Research Report 2025-2035 | Personalized Medicine and Precision Treatment Trends ...

Nasdaq Globe Newswire 24 Jul 2025
The Diffuse Large B-cell Lymphoma (DLBCL) market is witnessing significant growth, driven by advancements in targeted immunotherapies like CAR-T cell therapy and bispecific antibodies ... The Diffuse ...
Edit

Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma (Roche Holding AG)

Public Technologies 18 Jul 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 125445601) .
Edit

Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Genentech Inc)

Public Technologies 18 Jul 2025
Columvi (glofitamab-gxbm) is a prescription medicine to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that has come back (relapsed) or that ...
Edit

Diffuse Large B-Cell Lymphoma Clinical Trails, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis ...

GetNews 08 Jul 2025
DelveInsight’s, “Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2025,” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape.
Edit

Diffuse Large B-cell Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis ...

GetNews 25 Jun 2025
Diffuse Large B-cell Lymphoma current marketed and Diffuse Large B-cell Lymphoma emerging therapies ... Diffuse Large B-cell Lymphoma market drivers and Diffuse Large B-cell Lymphoma market barriers.
Edit

Roche Announces Global Phase III SUNMO Study Data for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Combination Therapy with Lunsumio and Polivy) (Chugai Pharmaceutical Co Ltd)

Public Technologies 23 Jun 2025
Roche Announces Global Phase III SUNMO Study Data for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Combination Therapy with Lunsumio and Polivy) ... Conference on Malignant Lymphoma (ICML).
Edit

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) (Genmab A/S)

Public Technologies 15 Jun 2025
... High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) ... About Diffuse Large B-Cell Lymphoma.
Edit

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular ...

Business Wire 13 Jun 2025
IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for IPH6501, ...
Edit

INNATE PHARMA HIGHLIGHTS PRECLINICAL ANTITUMOR ACTIVITY OF IPH6501 IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA AT THE 2025 EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS (Form 6-K) (Innate Pharma SA)

Public Technologies 13 Jun 2025
) INNATE PHARMA HIGHLIGHTS PRECLINICAL ANTITUMOR ACTIVITY OF IPH6501 IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA AT THE 2025 EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS.
Edit

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress (Innate Pharma SA)

Public Technologies 13 Jun 2025
... CD20+ B-cell non-Hodgkin lymphoma ... R-CHOP is an established standard of care for treatment-naïve patients with diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL), two subtypes of B-NHL.
Edit

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients (Roche Holding AG)

Public Technologies 23 May 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 124463091) .
Edit

New Two-Year Follow-Up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients (Genentech Inc)

Public Technologies 23 May 2025
Columvi (glofitamab-gxbm) is a prescription medicine to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that has come back (relapsed) or that ...
Edit

Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma (Roche Holding AG)

Public Technologies 20 May 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 124402682) .

Article Search

tools
×
×
×
×